uniQure Aims to Begin First Human Trial of Investigational Gene Therapy AMT-130 for Huntington’s in 2018 – Huntington’s Disease News
|
uniQure Aims to Begin First Human Trial of Investigational Gene Therapy AMT-130 for Huntington’s in 2018
Huntington’s Disease News uniQure expects to advance the clinical development of its Huntington’s disease investigational gene therapy, called AMT-130, during 2018. The company says it plans to file an investigational new drug application (IND) with the U.S. Food and Drug … |
Technology Networks |
Possible Biomarker to Identify Who Would Benefit from Immunotherapy
Technology Networks While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. “This begs the question: Why does it work in those patients? We don’t understand the mechanism at work … |
Labiotech.eu (blog) |
France Gets Ready to Test CAR-Treg Cells to Avoid Transplant Rejection
Labiotech.eu (blog) French biotech TxCell is finalizing the preparations to take its first cell therapy to clinical trials. The treatment, called HLA-A2 CAR-Treg, is intended for the prevention of chronic rejection after organ transplantation. Out of the €5M needed to … Government funds TxCell’s CAR-Treg therapyEuropean Biotechnology |
|
Welcome to London! Meet RebelBio’s Fifth Cohort of Biotech Startups
Labiotech.eu (blog) Irish accelerator RebelBio has launched its latest cohort of startups that will receive its support during a 3-month program at Imperial College London. RebelBio is a startup accelerator that helps entrepreneurs to build technology associated with the … |